ApiJect Systems

Patient Safety Movement Foundation’s Mid-Year Meeting Charts Course for Global Patient Safety Initiatives in 2024

Retrieved on: 
Saturday, January 27, 2024
Nursing, Public Policy, Government, Health, Healthcare Reform, Hospitals, Health Insurance, General Health, Momentum, Patient safety, World Health Organization, Patient, Hospital, Cause of action, Open data, Evidence-based medicine, Multimedia, ApiJect Systems, Summit, Competition, University, Algorithm, Johns Hopkins, PCAST, PSMF, Safety, Public health, ZERO, Approximation error

The Patient Safety Movement Foundation (PSMF) convened its annual Mid-Year Event to discuss safety challenges in the healthcare system that result in millions of preventable deaths around the world.

Key Points: 
  • The Patient Safety Movement Foundation (PSMF) convened its annual Mid-Year Event to discuss safety challenges in the healthcare system that result in millions of preventable deaths around the world.
  • View the full release here: https://www.businesswire.com/news/home/20240126619652/en/
    Patient Safety Movement Foundation Founder Joe Kiani speaks about the road ahead in global efforts to eliminate preventable patient harm at the PSMF's annual Mid-Year Event.
  • In 2012, Joe Kiani founded the non-profit Patient Safety Movement Foundation (PSMF) to eliminate preventable medical errors in hospitals.
  • His team worked with patient safety experts from around the world to create Actionable Evidence-Based Practices (AEBP) that address the top challenges.

Rice Biotech Launch Pad expands external advisory board with Kevin Sheridan

Retrieved on: 
Tuesday, October 17, 2023
Neuroscience, Jefferies, MBA, Bill & Melinda Gates Foundation, Massachusetts Institute of Technology, CTMC, Faculty, Rice, Launch pad, Columbia Business School, Rutgers University, Goldman Sachs, Rice University, Biotechnology, Green Launching Pad, MD Anderson Cancer Center, Harris Health System, Argonne National Laboratory, College of Engineering (KNUST), Growth, Chemistry, Geisinger Commonwealth School of Medicine, ApiJect Systems, Research, Integration, UBS, Pharmaceutical industry, Management

HOUSTON, Oct. 17, 2023 /PRNewswire/ -- Rice University today announced the addition of Kevin Sheridan to its external advisory board for the Rice Biotech Launch Pad, a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures. 

Key Points: 
  • HOUSTON, Oct. 17, 2023 /PRNewswire/ -- Rice University today announced the addition of Kevin Sheridan to its external advisory board for the Rice Biotech Launch Pad , a Houston-based accelerator focused on expediting the translation of the university's health and medical technology discoveries into cures.
  • "With the formation of the external advisory board earlier this month , the Rice Biotech Launch Pad is well-positioned to stand out among other accelerators and to have a meaningful impact on the biotech industry with the invaluable insights provided by the board," said Omid Veiseh , associate professor of bioengineering at Rice and faculty director of the accelerator.
  • "Kevin is the next piece of the puzzle to building out the phenomenal group of executives that comprise our external advisory board.
  • Sheridan is the 12th member of the Launch Pad's external advisory board.

ApiJect Systems, Corp. Bolsters Global Health Team with Esteemed Anthropologist and Leading Expert on Vaccine Hesitancy, Dr. Heidi J. Larson, as Senior Advisor

Retrieved on: 
Wednesday, October 4, 2023
Communication, Risk, Stuck: How Vaccine Rumors Start and Why They Don't Go Away, University, Institute for Health Metrics and Evaluation, BBC, Health education, University of Washington, World Health Organization's response to the COVID-19 pandemic, COVID-19, Senior advisor, ApiJect Systems, Research, Vaccine hesitancy, Doctor of Philosophy, Theory, UNICEF, Thought, Vaccine Confidence Project, Patient, Evaluation, Platform, Tropical medicine, Global North and Global South, Hygiene, Health, Immunization, Woman, Clinical, London School of Hygiene and Tropical Medicine, Management, Vaccine, Anthropology

Dr. Larson is best known for groundbreaking research that advances the medical, scientific, social, and political understanding of vaccine hesitancy.

Key Points: 
  • Dr. Larson is best known for groundbreaking research that advances the medical, scientific, social, and political understanding of vaccine hesitancy.
  • She has engaged in effective advocacy for better health education and policies by building consensus and critical partnerships that influence health interventions and shape policies.
  • She is the Founder and Director of The Vaccine Confidence Project, which since 2010 has worked throughout the world to overcome vaccine hesitancy.
  • She has published extensively on the topic, including her book, STUCK: How Vaccine Rumors Start—and Why They Don't Go Away.

Advent International and Warburg Pincus Name Franco Negron CEO of BioPharma Solutions Following its Proposed Divestiture from Baxter

Retrieved on: 
Thursday, August 24, 2023
IC Group, Partnership, Modernizing Medicine, ICE, Health care, Summit Health, Bausch Health, ApiJect Systems, Thermo Fisher Scientific, Baxter International, Warburg Pincus, Bausch & Lomb, Development, CDMO, Syneos Health, Novartis, Investment, Advent, Advent International, Commercial Operating System, Commercial, NYSE, BPS, McNeil Consumer Healthcare, Pharmaceutical industry, Industrial design

BOSTON and NEW YORK, Aug. 24, 2023 /PRNewswire/ -- Advent International ("Advent"), one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor, today announced they have selected Franco Negron to be chief executive officer (CEO) of BioPharma Solutions (BPS) following its proposed divestiture from Baxter International Inc. (NYSE:BAX).

Key Points: 
  • BOSTON and NEW YORK, Aug. 24, 2023 /PRNewswire/ -- Advent International ("Advent"), one of the largest and most experienced global private equity investors, and Warburg Pincus, a leading global growth investor, today announced they have selected Franco Negron to be chief executive officer (CEO) of BioPharma Solutions (BPS) following its proposed divestiture from Baxter International Inc. (NYSE:BAX).
  • Mr. Negron is a highly accomplished leader with nearly 30 years of experience in the pharmaceutical industry.
  • Most recently, he served for three years as the CEO of ApiJect Systems America.
  • Mr. Negron has also held senior positions at other leading pharmaceutical companies, including Valeant Pharmaceuticals, Novartis and McNeil Consumer Healthcare.

Revolutionizing Prefilled Injectables through Innovative Technology, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, June 14, 2023
COVID-19, FDA, Safety, ApiJect Systems, Administration, Vaccine

TORONTO, June 14, 2023 /PRNewswire-PRWeb/ -- As the demand for parenteral products increases, companies are seeking solutions that offer the benefits of prefilled formats while reducing lead times and costs associated with sterile fill-finish services. The projected growth of sterile injectables in the next decade makes finding such solutions crucial. The integration of innovative technology, aseptic manufacturing, and injection molding presents a supply chain that is both flexible and resilient, even during global crises such as the COVID-19 pandemic.

Key Points: 
  • Attendees will learn about the next-generation advanced aseptic fill & finish technology for prefilled single-dose sterile injectables and its impact on the pharmaceutical industry.
  • The featured speakers will discuss the history of injectables and the changing demands of customers for enhanced drug delivery systems.
  • The speakers will emphasize the logical progression with a focus on integrating quality, convenience, and safety into innovative technology.
  • Register for this webinar to learn how scalable fill-finish, a compact supply chain and cost-efficient manufacturing can solve drug delivery challenges for prefilled injectables.

Corium Pharma Solutions Names Two Industry Veterans to its Executive Team

Retrieved on: 
Thursday, February 9, 2023
Saint Joseph's University, Niraj, ApiJect Systems, Therapy, Alzheimer's disease, Rare, International business, Crest Whitestrips, Publication, Intellectual property, PG, NYSE, State university system, Acquisition, Patient, Business, Business development, University, Research, Rensselaer Polytechnic Institute, Temple University School of Pharmacy, Area under the curve (pharmacokinetics), FDA, Growth, Avior, MS, BS, Indian Institutes of Technology, Chemical engineering, Management, Pharmaceutical industry, Pharmacy, Biology, Corium

GRAND RAPIDS, Mich., Feb. 9, 2023 /PRNewswire/ -- Corium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer.  These appointments, including CPSI's recent announcement that Mark Sirgo had been named Chief Executive Officer, further strengthen CPSI's executive team and position the company for long-term growth.

Key Points: 
  • These appointments, including CPSI's recent announcement that Mark Sirgo had been named Chief Executive Officer, further strengthen CPSI's executive team and position the company for long-term growth.
  • Dr. Niraj Vasisht brings more than 25 years of experience as an executive, entrepreneur, and technology key-opinion-leader in drug delivery to the pharmaceutical industry.
  • As Chief Technology Officer, Niraj will play a critical role overseeing the formulation development work behind all of our CPSI platforms.
  • Founded in 1995 in Grand Rapids, Michigan, Corium Pharma Solutions has maintained longstanding partnerships with multinational Fortune 500 companies and pharmaceutical businesses alike.

ApiLabs, R&D Sister Company to ApiJect, Launches Its Field Research Network

Retrieved on: 
Thursday, September 15, 2022
Laboratory, Safety, Woman, MD, ApiJect Systems, Organization, Environment, Head, Patient, Reproductive health, OBE, Doctor of Philosophy, Research, GLOBE, Medical device

GENEVA, Sept. 15, 2022 (GLOBE NEWSWIRE) -- ApiLabs, an R&D company developing innovative, affordable medical technologies to maximize healthcare access for patients in all world regions, has launched its ApiLabs Field Research Network (AFRN).

Key Points: 
  • GENEVA, Sept. 15, 2022 (GLOBE NEWSWIRE) -- ApiLabs, an R&D company developing innovative, affordable medical technologies to maximize healthcare access for patients in all world regions, has launched its ApiLabs Field Research Network (AFRN).
  • Resulting information helps ApiLabs engineers develop medical devices for all global markets, which its sister company ApiJect Systems then helps commercialize with pharmaceutical partners.
  • "Our Field Research Network is vital in the development of medical devices that truly meet the needs of local populations anywhere in the world," said Edward Kelley, PhD, ApiLabs' Chief Global Health Officer.
  • "Historically, medical devices for global markets have been designed in laboratories with far too little interaction and feedback from field healthcare personnel and their patients."

ApiJect Announces Investment by Royalty Pharma and Jefferies

Retrieved on: 
Wednesday, May 18, 2022
Risk, RNA transfection, Engineering, Jefferies, ApiJect Systems, Public health, JEF, Multimedia, Patient, Goal, View, Vaccine, Solution, Health, Association, Hanjin Shipping, GameChanger, FDA, Royalty Pharma, Partnership, Time, Board, Technology, Advanced Technology Development Center, Temperature, BFS, Founder, Jefferies Financial Group, NYSE, CEO, Security (finance), Pharmaceutical industry, Fine chemical

STAMFORD, Conn., May 18, 2022 /PRNewswire/ -- ApiJect Holdings, Inc., the parent company of ApiJect Systems, Corp., a medical technology public-benefit corporation transforming the fill and finish and delivery of injectable vaccines and medicines, announced today that it had completed a $111 million private round of investment.

Key Points: 
  • ApiJect Announces Investment $111 Million Equity Investment Round by Royalty Pharma and Jefferies.
  • The new round was led by Royalty Pharma and Jefferies Financial Group (NYSE: JEF), which acquired a revenue interest in addition to equity.
  • Jefferies and ApiJect's other lenders also converted all of their debt into ApiJect equity, such that following this transaction, ApiJect has no debt on its balance sheet.
  • The investment provided by Royalty Pharma and Jefferies supports further development of an injection technology that can scale rapidly and efficiently to meet global demand for injectable medicines."

ApiJect Systems Announces the Opening of the ApiJect Technology Development Center in Greater Orlando, FL

Retrieved on: 
Wednesday, April 13, 2022
BFS, CEO, Judgement, U.S. Department of Defense Strategy for Operating in Cyberspace, ASPR, HHS, Center, ApiJect Systems, Government, Patient, Technology, Machinist, Vaccine, Temperature, CGMP, Chief executive officer, Unitary state, Assistant, Multimedia, Pandemic, Partnership, Florida Council of 100, Pharmaceutical industry, Engineering, Central Florida

STAMFORD, Conn., April 13, 2022 /PRNewswire/ -- ApiJect Systems, Corp., a medical technology public-benefit corporation that will transform how injectable vaccines and medicines are filled, finished, and delivered, announced today the launch of the ApiJect Technology Development Center in greater Orlando, FL.

Key Points: 
  • STAMFORD, Conn., April 13, 2022 /PRNewswire/ -- ApiJect Systems, Corp., a medical technology public-benefit corporation that will transform how injectable vaccines and medicines are filled, finished, and delivered, announced today the launch of the ApiJect Technology Development Center in greater Orlando, FL.
  • The ApiJect Center also enables the fill-finish of smaller batch sizes for feasibility testing and device use testing, leading to commercial development.
  • ApiJect Chief Executive Officer Jay Walker commented: "The ApiJect Center is where the future of injection technology will be created.
  • The ApiJect Center, here in Central Florida, will be launchpad for the future of injectable device technology."

ApiJect Announces Ed Kelley, PhD, as Chief Global Health Officer for ApiJect Systems and Affiliated Organizations

Retrieved on: 
Wednesday, March 30, 2022
ACT, Accelerator, Research, Nursing care plan, The Global Fund to Fight AIDS, Tuberculosis and Malaria, Vaccine, Global health, Partnership for Refugees, Public health, Office of Inspector General, U.S. Department of Health and Human Services, TB, ApiJect Systems, HHS, Johns Hopkins University, Partnership, D-8 Organization for Economic Cooperation, Access, Organization, Patient safety, Policy, Socioeconomics, Dartmouth College, Primary health care, World Health Organization, WHO, Agency for Healthcare Research and Quality, SIGN, Doctor of Philosophy, World, Global Initiative, Government, USAID, Foundation (nonprofit), Johns Hopkins Bloomberg School of Public Health, Associate professor, Agency, COVID, Awareness, Patient, Bill & Melinda Gates Foundation, QAP, Health, Rockefeller Foundation, COVID-19, GAVI, News, HIV, Pharmaceutical industry, Management, Malaria

STAMFORD, Conn., March 30, 2022 /PRNewswire/ -- ApiJect Systems, Corp., a medical technology public-benefit corporation providing a platform that enables pharmaceutical and biotech companies to efficiently fill-finish their injectable medicines in prefilled delivery systems, has announced that Edward Kelley, PhD, has joined the company as Chief Global Health Officer for ApiJect and as a leader of its related organizations, ApiLabs and the ApiJect Global Initiative.

Key Points: 
  • Dr. Kelley also serves as the Chief Global Health Officer of ApiLabs, an ApiJect sister company that performs ground-level R&D on new, scalable medical devices created on the ApiJect Platform.
  • Marc Koska OBE, inventor of the widely-used K1 auto-disable syringe and co-founder of ApiJect, serves as the lead designer at ApiLabs.
  • In welcoming Dr. Kelley, ApiJect Chairman Jay Walker stated, "Ed Kelley is among the world's most accomplished leaders in public health.
  • His knowledge of global health, plus his passion and commitment adds to the capability of the ApiJect organization.